We also demonstrated that expression of phosphorylated 4E-binding protein 1 (p4EBP1), a downstream target of the PI3K pathway, may have potential as an efficacy-linking marker of combination treatment with AKT and HER2 inhibitors in patients with HER2+ breast cancer with PIK3CA mutations. Here, PIK3CA is linked to breast carcinoma.